Ludwig Enterprises announces AI-powered cheek swab cancer screening technology Revealia

LUDWIG ENTERPRISES, INC.

Revealia uses AI-driven analysis of mRNA genetic signals from a mail-order non-invasive cheek swab to detect early signs of cancer.
Proprietary Revealia Inflammatory Index (RII) quantifies cancer risk using machine learning that continuously improves with new patient data.
Analysis based on mRNA samples from over 40 multipurpose medical clinics across the United States.
No specific launch date, financial projections, or regulatory status disclosed in the announcement.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.